Effect of a community screening for Helicobacter pylori: A 5-yr follow-up study

American Journal of Gastroenterology

Volumn 103, Issue 5, 2008, Pages 1106-1113

  Hansen, Jane M ^a   Wildner Christensen, Mette ^a   Hallas, Jesper ^b   Schaffalitzky De Muckadell, Ove B ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTACID AGENT; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL LEAVE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REGISTER; STOMACH CANCER; SYMPTOM;

ADULT; AMOXICILLIN; ANTI-ULCER AGENTS; CLARITHROMYCIN; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DENMARK; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MASS SCREENING; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER;

EID: 43549126890     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01770.x     Document Type: Article

References (20)

1. Fendrick A, Chernew M, Hirth R, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999 159 : 142 8.
2. Parsonnet J, Harris R, Hack H, et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996 348 : 150 4.
3. Moayyedi P, Soo S, Deeks B, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006 4 CD001960.
4. El-Serag H, Talley N. Systematic review: The prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004 19 : 643 54.
5. Wildner-Christensen M, Hansen J, Schaffalitzky de Muckadell O. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003 125 : 149 54.
6. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988 33 : 129 34.
7. Ware JJ, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
8. Lassen A, Petersen F, Bytzer P, et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomized trial. Lancet 2000 356 : 455 60.
9. Kjøller M, Rasmussen N, Keiding L, et al. Sundhed og sygelighed i Danmark 1994: Og udvikling siden 1987: Rapport fra DIKEs repræsentative undersøgelser blandt voksne danskere. København, Denmark : DIKE, 2006.
10. Arroyo M, Forne M, Argila C, et al. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drugs is negligible in Southern Europe. Helicobacter 2004 9 : 249 54.
11. Vergara M, Catalan M, Gispert J, et al. Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005 21 : 1411 8.
12. Lassen A, Hallas J, Schaffalitzky de Muckadell O. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: A population-based cohort study. Am J Gastroenterol 2006 101 : 945 53.
13. Ohmann C, Imhof M, Ruppert C, et al. Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 2005 40 : 914 20.
14. Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003 10 : 148 56.
15. Torgerson D, Roland M. Understanding controlled trials: What is Zelen's design? BMJ 1998 316 : 606.
16. Lane J, Murray L, Noble S, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter project: Randomized controlled trial. BMJ 2006 332 : 199 204.
17. Moyyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomized controlled trial. Lancet 2000 355 : 1665 9.
18. Ford A, Forman D, Bailey A, et al. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2006 129 : 1910 7.
19. Lassen A, Hallas J, Schaffalitzky de Muckadell O. First-time endoscopy and use of antisecretory medication: A population-based cohort study. Scand J Gastroenterol 2005 40 : 705 12.
20. Lassen A, Hallas J, Schaffalitzky de Muckadell O. The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication. Gastroenterology 2005 129 : 1179 86.